A CLINICAL CASE OF CROHN’S DISEASE
Abstract
The article demonstrates a clinical case of Crohn’s disease. The clinical manifestation of the disease, a diagnostic approach based on laboratory and instrumental methods with discussion of obtained results, and the up-to-date methods of investigation based on the literature data are shown. The significance of lifestyle modification, optimal drug treatment and regular check-ups for improvement of prognosis is emphasized. TreatmentGeneral approach includes smoking cessation; lactose-free diet in case of secondary lactose intolerance which is present in approximately one third of cases; in the case of malabsorption syndrome appropriate replacement of vitamins, calories, protein, zinc, calcium and other nutrients is considered. Treatment bile acid diarrhea includes administration of ion-exchange resins to bind bile acids (e.g., cholestyramine).During acute episodes recommendations to avoid dietary fibers should be given and parenteral nutrition can be prescribed.Our patient received drug therapy: reosorbilact solution 200,0ml during four. The goal of treatment of CD is thus to slow the progression of the disease, avoid recurrence of inflammatory episodes and prevent complications which are extremely common in the absence of optimal treatment. Life expectancy is normal and quality of life may be satisfactory with aggressive evidence-based treatment. Majority of patients (approximately 70%) requires surgical operations due to complications within 15years of their onset.
Downloads
References
Fakhoury M. Inflammatory bowel disease: clinical aspects and treatments / M. Fakhoury, R. Negrulj,
A. Mooranian, H. Al-Salami // Journal of Inflammation Research. – 2014. – No. 7. – p. 113–120.
Ha F. Crohn's disease: a clinical update / F. Ha, H. Khalil // Therap. Adv. Gastroenterol. – 2015. – No 8(6). – p. 352–359.
Takeuchi K. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease / K. Takeuchi, S. Smale, P. Premchand, et al.] // Clin Gastroenterol Hepatol. – 2006. – No 4(2). – p. 196–202.
Cambridge G. Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role /G. Cambridge, D. S. Rampton, T. R. J. Stevens et al] // Gut. - 1992. – No 33(5). – p. 668–674.
Lecis P. p-ANCA and ASCA antibodies in the differential diagnosis between ulcerative rectocolitis and Crohn's disease / P. Lecis, B. Germanà, N. Papa et al] // Recenti progressi in medicina. – 2002. – No 93(5). – p. 308–313.
Di Ruscio M. Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin? // M. Di Ruscio, F. Vernia, A. Ciccone et al.] // Inflamm. Bowel. Dis. – 2017. – No 24(1). – p. 78–92.
Al-Bawardy B. Endoscopic and Radiographic Assessment of Crohn's Disease / B. Al-Beardy, S. L. Hansel, J. L. Fiddler, et al.] // Gastroenterol Clin North Am. – 2017. – No 46(3). – p. 493–513.
The Journal of V. N. Karazin Kharkiv National University, series Medicine has following copyright terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
